When Topical Rx Therapies Are Not Enough…
Improvement in Disease Extent and Severity

In 3 pivotal trials, adult patients with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT 300 mg Q2W or placebo. In Trial 3, concomitant TCS was used. An endpoint measured included the proportion of subjects with EASI-75 (improvement of ≥75% in Eczema Area and Severity Index [EASI] score from baseline).1,2

Long-lasting Skin Clearance

18+ years

Sustained at least 75% improvement in lesion extent and severity (EASI-75) up to 52 weeks with DUPIXENT + TCS in Trial 3 (secondary endpoint)3,4,a,b

Trial 3: Concomitant Therapy With TCS

Patients achieved significantly more improvement in lesion extent and severity across monotherapy trials at Week 16 (secondary endpoint).1

  • 51% and 44% of DUPIXENT patients achieved at least a 75% improvement in lesion extent and severity (EASI-75) vs 15% and 12% with placebo at 16 weeks in Trials 1 and 2, respectively (P<0.001)1,5
  1. In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.
  2. Full Analysis Set includes all subjects randomized.
  3. Week 52 data were limited to patients completing 52 weeks as of the cutoff date.

Measuring Disease Extent and Severity and Patient-Reported Eczema Symptoms

EASI combines the severity of the signs of eczema and the extent of skin involvement.2

The severity of each of 4 eczema signs is assessed on a scale of 0 to 36

The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6. Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least.2,6

Each region gets a total region score: Severity Score x Area Score x Multiplier = Region Score

The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.2,6

An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.1

Dosing and
Administration
Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
DUPIXENT MyWay Get patient access support
and information about benefits
investigations, prior authorizations,
and Medical Necessity and
appeal letters.
Explore Patient Support Resources
References:
  1. DUPIXENT Prescribing Information.
  2. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357.
  3. Data on file, Regeneron Pharmaceuticals, Inc.
  4. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  5. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  6. EASI User Guide. HOME–Harmonising Outcome Measures for Eczema. Accessed March 11, 2020. www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf.